QL-X-138 is a potent and selective BTK and MNK dual kinase inhibitor that binds covalently to BTK and non-covalently to MNK.The IC 50 s of QL-X-138 against BTK, MNK1 and MNK2 kinases are 9.4 nM, 107.4 nM and 26 nM, respectively.The IC 50 s of QL-X-138 against Dengue 2 is 3.5 μM.QL-X-138 is used in the study of B-cell malignancies. QL-X-138 inhibits dengue virus 2 with an IC 50 of 3.5 μM. QL-X-138 can be used in the study of B-cell malignant tumors.

98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

QL-X-138 (0.5-5 μM; 24-72 h) arrests the progression of Ramos, OCI-AML-3, U937, and U2932 cells cycle in a dose-dependent manner[1].
QL-X-138 (0.5-5 μM; 8-72 h) induces apoptosis of Ramos, OCI-AML-3, U937 and U2932 cells in a time- and dose-dependent manner.[1]
QL-X-138 (3-10000 nM; 4 h) blocks BTK- and MNK-mediated signaling in lymphoma and leukemia cells.[1]
QL-X-138 (72 h) demonstrates anti-proliferative activity against lymphoma and leukemia cell lines, with GI50 values of 0.31, 1.2, 0.49, 1.4, 0.4, 0.23, 0.95, 1.2, 1.4, 0.23, 1.3, 0.93, 1, and 2.4 μM for TMD8, U2932, Ramos, OCI-AML3, SKM-1, NOMO-1, NB4, HEL, U937, NALM6, MEC-1, MEC-2, Hs 505.T, and REC-1 cells, respectively.[1]